Biological Variation of Brain Natriuretic Peptide and Cardiac Events in Stable Outpatients With Nonischemic Chronic Heart Failure
Open Access
- 1 January 2011
- journal article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 75 (2) , 341-347
Abstract
Background: To evaluate the biological variation and prognostic value of brain natriuretic peptide (BNP) for stable outpatients with nonischemic chronic heart failure (NICHF). Methods and Results: Biological variation in BNP was evaluated using an automated assay system in 140 outpatients with NICHF. The stable clinical condition during the 2-month study period was defined as unchanged NYHA and unchanged left ventricular ejection fraction; therefore, 7 patients were excluded during the 2 months. Thereafter, 133 patients were prospectively followed and the relationship between cardiac events and the plasma BNP concentrations (at baseline and after 2 months) were evaluated as well as the changes in BNP. The biological variation in BNP (2-month interval) was calculated as 22.3%. During a mean follow-up period of 42 months, 26 patients had cardiac events. According to stepwise multivariate analyses, plasma BNP after 2 months (P=0.0002) and % change in BNP (P=0.0067) were significant independent predictors of cardiac events. Conclusions: These findings indicated that a combination of the absolute value of BNP after 2 months and % increase in BNP (2-month interval) is useful for predicting cardiac events in stable outpatients with NICHF. (Circ J 2011; 75: 341-347)Keywords
This publication has 38 references indexed in Scilit:
- Dose-Dependent Prognostic Effect of Carvedilol in Patients With Chronic Heart Failure Special Reference to Ranscardiac Gradient of NorepinephrineCirculation Journal, 2009
- Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3Circulation Journal, 2008
- Direct Comparison of Transcardiac Difference Between Brain Natriuretic Peptide (BNP) and N-Terminal Pro-BNP in Patients with Chronic Heart FailureEuropean Journal of Heart Failure, 2007
- Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) DataClinical Chemistry, 2006
- Prognostic information provided by serial measurements of brain natriuretic peptide in heart failureInternational Journal of Cardiology, 2004
- N-terminal pro-brain natriuretic peptide A new gold standard in predicting mortality in patients with advanced heart failureEuropean Heart Journal, 2003
- Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Circulation, 2003
- High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failureJACC, 2000
- Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995American Heart Journal, 1999
- Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart FailureCirculation, 1997